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Abstract 
Background: Previous studies have demonstrated probable involvement of immune 
activation and selective immune dysfunction in patients with somatoform disorders (SFD). 
The aim of the present study was to investigate if SFD are associated with changes in the 
normal serum levels of important interleukins and further, to establish if these changes are 
related to the presence and severity of alexithymia (reduced ability to identify and express 
emotions) in the patients with SFD.  
Methods: Twenty-four patients who met ICD-10 diagnostic criteria for SFD completed the 
psychological questionnaire to assess alexithymia (TAS-scale), symptom reporting (SCL-90-
R) and diagnostic for SFD (SOMS-scale). Serum concentrations of soluble interleukin 2 
receptor alpha (sIL-2 Rα), IL-4, IL-6, IL-10, IL-12 were determined in patients with SFD and 
in nine healthy subjects. 
Results: Patients with SFD exhibited elevated levels of alexithymia compared to population 
norms, with particularly high scores on the “Difficulty identifying feelings” sub-scale of the 
TAS-26. Furthermore, serum levels of IL-6 (p<0.001) and IL-10 (p=0.047) were significantly 
increased in patients with SFD in comparison to healthy controls. Additionally a negative 
correlation was observed between the level of alexithymia (total TAS-score) and the serum 
levels of sIL-2 Rα (r=-0.538). Taken together these results suggest that SFD, with clinically 
significant alexithymia, are associated with a reduction in TH1 mediated immune function 
and an increase in the activation of the TH2 immune function, indicated by the augmented 
serum levels of the interleukins (6 and 10).  
Conclusions: These data suggest that alexithymia is associated with chronic activation of the 
immune system and may be critically involved in the pathophysiology of bodily symptoms in 
SFD. 
Key words: Somatoform disorders - Immunology -Interleukin - Alexithymia - IL-6 - IL-10 - 
sIL-2 Rα 
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Abbreviations: SFD = Somatoform Disorders; TAS-26 = 26-Item Toronto Alexithymia Scale; 
SCL-90-R = Symptom Checklist-90 Revised; IL = Interleukin; SOMS = Screening for 
Somatoform Symptoms scale; sIL-2 Rα = Soluble interleukin-2 receptor α. 
 
 
1. Introduction 
In 1980 the DSM-III introduced the category of somatoform disorders (SFD) as a provisional 
grouping of psychiatric conditions characterized by often multiple and variable somatic 
symptoms – commonly seen in general medical practice and primary care – but defying 
medical explanation (Ustun and  Sartorius, 1995). It is clear from their high lifetime 
prevalence (4-5%) in the general population (Swartz et al., 1986; Escobar et al., 1987, 1998), 
their high comorbidity with other conditions, their debilitating effect on patients, and their 
association with high levels of drug use, that SFD are of great clinical and economic 
importance (Barsky et al., 2005).  
 
Previous studies (e.g. Bach & Bach, 1995; Bankier et al., 2001) have reported that, relative 
to healthy participants, patients with SFD exhibit elevated levels of alexithymia. Alexithymia 
is a concept that was developed by Sifneos (1973) and means literally “absence of words for 
emotion”. Alexithymia is characterised by an inability to describe and identify feelings, by an 
absence of fantasies, and by the tendency to utilise an externally focused analytical cognitive 
style. The concept of alexithymia has been examined in a variety of different medical, 
psychosomatic and psychiatric disorders (Naatanen et al., 1999; Sifneos, 2000; Wise et al., 
2000). The findings of these studies support the conceptualisation of alexithymia and the 
clinical impression of an association between somatization and alexithymia (Bankier et al., 
2001; Lundh & Simonsson-Sarnecki, 2001).  
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Previous research (e.g. Singh & Fudenberg, 1986) has proposed an important relationship 
between the central nervous system (CNS), the endocrine system, and the immune system, 
that mediates neuroendocrine regulation of immune function. Furthermore, a number of 
studies (e.g. Dantzer et al., 1998; Pollmächer et al., 2002; Dantzer, 2005) have identified a 
key role for cytokines such as Interleukin-1 (IL-1), IL-6 and tumour necrosis factor (TNF-α) in 
the interaction between the immune and central nervous systems. For example, 
administration of cytokines (rIL-2 & IL-6) has been shown to induce a number of psychiatric 
symptoms; most notably depressed mood, apathy, fatigue (Walker et al., 1997; Späth-
Schwalbe et al., 1998). Moreover, Kelly-Welch et al. (2005) reported that the deregulation of 
anti-inflammatory cytokines such as IL-4 may lead to a disturbance of the type1/type2 
cytokine balance. A major consequence of this cytokine imbalance is an increase in TH2 
response, with a resultant increase IgE antibody synthesis (a type of immunoglobulin usually 
released during an allergic reaction) leading to an inflammatory response in the body.   
 
As noted earlier, SFD are associated with bodily symptoms (most notably pain) which cannot 
be adequately explained by organic causes. With this in mind, it is notable that previous 
studies (e.g. Schaefer & Stein, 1999) have reported that certain cytokines can stimulate 
inflammatory pain. It would seem plausible that the inflammatory response of the immune 
system (mediated by cytokines) might underlie the illness symptoms reported by patients 
with SFD.  However, contrary to this notion, Rief et al. (2001) reported that patients with 
somatization syndrome actually exhibited changes in immune function that are associated 
with a moderate reduction in the inflammatory response, such as reduced levels of 
proinflammatory cytokines such as IL-6, and lowered CD8 (lowered T-lymphocytic activity), 
and yet on the other hand increased interleukin-1 receptor-antagonist (IL-1RA) with 
monocytic activation. This apparent inconsistency is worthy of further study. 
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As noted previously, alexithymia is related to an increase in the bodily expression of 
emotional distress. With this in mind, it is plausible that high levels of alexithymia would be 
associated with changes in immune function. In line with notion, Todarello et al. (1994, 1997) 
reported higher levels of alexithymia in patients with cervical intraepithelial neoplasia 
(precancerous lesions of cervix) compared to patients without such lesions. Furthermore, 
they reported lower counts of almost all lymphocyte subsets in the alexithymic patients 
compared to the non-alexithymic patients. Similarly, Dewaraja et al. (1997) reported that 
healthy men categorised as highly alexithymic (based on their scores on the TAS) exhibited 
decreased cytotoxic lymphocyte counts (for natural killer subset CD57-CD16+ cells and killer 
effective T cell CD8+CD11a+ cells) compared to non-alexithymic men. Corcos et al. (2004) 
examined alexithymia, mood (depression & anxiety) and serum levels of the different 
cytokines in a group of seventeen healthy women and found a positive correlation between 
the participants’ scores on alexithymia scale (TAS) and their serum levels of IL-4. A similar 
relationship was observed between the participants’ scores on the “difficulty identifying 
feelings” subscale of the TAS and their observed serum levels of IL-4. A stepwise multiple 
regression revealed that TAS scores were the only variables that predicted IL-4 levels; as 
depression, age, and body mass index (BMI) did not enter as significant predictors. It is 
notable that Corcos et al. (2004) were unable to obtain detectable levels of IL-1 and IL-2 in 
the majority of their sample, thus they were unable to establish if alexithymia was related to 
changes in the serum levels of these cytokines. 
 
As there have only been a few studies examining activation of the inflammatory response 
system (IRS) and changes in immunological variables in SFD (Rief et al., 2001; Dantzer, 
2005) it is important to extend this research in order to develop our understanding of the role 
of the immune response in SFD. Similarly, as there has been relatively little research 
addressing the effects of alexithymia on the immune function (e.g., Corcos et al., 2004; 
Guilbaud et al., 2003; Todarello et al., 1994; 1997) it is essential to make advances to this 
work. Considering that patients with SFD have been shown to exhibit elevated levels of 
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alexithymia (Bach & Bach, 1995; Bankier et al., 2001) it is plausible that the observed 
changes in the immune function of patients with SFD might relate to differences in 
concomitant alexithymia. However, as yet, there has been no study that has examined the 
relationship between alexithymia and cytokine production in participants with SFD. 
Therefore, the aim of the present study was to conduct such an investigation. 
In the present study, serum levels of key interleukines (IL-6, IL-4 IL-10, IL-12, sIL-2 Rα) were 
systematically examined in a group of patients with SFD and a group of healthy controls. The 
presence and severity of alexithymia in patients with SFD was also established using the 
TAS-26. In line with previous work we expected a higher incidence of alexithymia in SFD 
compared to the population norms reported in Kupfer et al. (2000; 2001). Second, it was 
predicted that there would be changes in the serum levels of the key cytokines in the patients 
with SFD relative to the healthy controls. Furthermore, it was expected that these changes in 
serum levels would be significantly correlated with the patients’ alexithymia (TAS-26) scores. 
 
2. Methods 
2.1. Participants 
Twenty-four patients (16 females, 8 males) meeting ICD-10 criteria for SFD and nine healthy 
controls (4 females, 5 males) took part in the present study. Ten of the SFD patients were 
diagnosed with somatization disorder (F45.0); 13 with somatoform autonomic dysfunction 
(F45.3); and one with persistent somatoform pain disorder (F45.4). The characteristics of the 
patients are presented in Table 1. The patients with SFD were recruited from an outpatient 
clinic of the Department of Medicine (Munich University), where they had been referred for 
diagnostic interview and counselling in psychiatric and psychosomatic field. Inclusion criteria 
for the patient group were the presence of SFD diagnosed according to ICD-10 criteria. The 
diagnosis was established through a clinical interview conducted by a trained psychiatrist 
(P.G.F.), who performed extensive physical and psychological assessment of the patients; 
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including checking for the signs and symptoms of SFD as outlined in the diagnostic criteria 
cited in the ICD-10 (Hiller et al., 1996). A further aid to the diagnosis of SFD was that the 
participants’ fulfil the criteria on the SOMS questionnaire (Rief et al., 1997). Exclusion criteria 
were presence of other psychiatric disorders (e.g. psychosis, substance abuse disorders, & 
major affective disorders), medication with benzodiazepines or other psychotropic 
medication, steroid-hormone intake and contraceptive medication during the past four weeks. 
The patients were thus in principle drug free in order to minimize pharmacological influence if 
possible. The presence of an acute or chronic infection or recent history of an infectious 
disease (e.g. influenza) within the past four weeks was a further exclusion criterion, as was 
the presence of a serious medical disease (e.g. autoimmune-, neoplasms, cardiac-, 
pulmonary-, or endocrine diseases). It should be noted that there was a high level of 
psychiatric comorbidity in the patient sample, as twenty-three of the twenty-four patients 
exhibited significant symptoms of other psychiatric disorders. The most common comorbid 
disorder (n = 17) was dysthymia (F34.1). Depressive reaction (F43.2) was the next most 
common disorder (n = 4). There was also one case of an anxiety disorder (F41.1) and one 
case of neurasthenia (F48.0). For age and educational level there are no statistically 
significant differences between patient group with SFD and healthy subjects. The participants 
(n=9) in the healthy control group were recruited from hospital employees and from the 
student population at the University of Munich. The nine healthy volunteers were included 
following a medical examination (medical and psychiatric history) and establishment of 
normal laboratory parameters (including normal values of including hematological screening, 
blood chemistry with glucose, total protein, total bilirubin, liver enzymes, electrolytes, 
creatinine, urea, uric acid, cholesterol, triglycerides, semiquantitative urinalysis, and thyroid 
hormones, c reactive protein, luteinizing hormone, folliculo-stimulating hormone, prolactin, 
progesterone, oestrogens, testosterone). In general they were in good general health and 
there was no evidence of a serious medical disease (like autoimmune-, neoplasms, cardiac-, 
pulmonary-, or endocrine diseases) or a psychiatric disorder (e.g. depression or anxiety) in 
any of the participants in the control group. As the controls were screened for psychological 
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disturbance prior to inclusion in the study it was not considered necessary to conduct the 
same detailed psychological measurement that was conducted on the patients with SFD. In 
common with the (SFD) patient group, regular drug intake, the presence of acute or chronic 
infection and/or a recent history of an infectious disease (e.g. influenza) within the past four 
weeks were the exclusion criteria. Female subjects were not taking birth control pills, had 
regular menstrual cycles, but actual menstrual status was not considered. The study protocol 
was approved by the Ethical Committee of the University Munich in accordance with the 
declaration of Helsinki. Full written informed consent was obtained from each participant 
before study inclusion.  
 
2.2. Materials and Procedure 
Participants fulfilling the inclusion criteria were invited to participate in the study and were 
assessed using a number of psychological measures. Blood serum levels of the different 
interleukines were also established for the two participant groups.   
2.3. Questionnaires and Measures 
The SOMS (Rief, 1997) is a self-rating questionnaire checking for 53 physical symptoms. The 
questionnaire includes all 33 physical complaints of the DSM-IV somatization disorder 
symptom list, the symptoms of ICD-10 somatization disorder, and the ICD-10 somatoform 
autonomic dysfunction symptom list. This questionnaire requires the participants to report if 
they had experienced any or all of 53 physical symptoms during the past 2 years. They were 
instructed only to answer "yes" if the symptoms had a significant influence on their subjective 
well being and if doctors did not find a sufficient explanation for the complaints. Thus, 
persons with physical illness were not excluded but were instructed only to report physically 
unexplained symptoms. Item 54 to item 68 of the SOMS cover all inclusion and exclusion 
criteria (first complaints before age 30 years, symptom duration, acceptance of doctor’s 
explanation that the complaints do not have a physical origin, doctor visits due to the 
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symptoms, etc.). Adding the number of positively answered symptoms allows computation of 
the "somatization severity index" (range from 0 to 33 points), which we also used in our study 
to categorise the SFD patients. The number of somatization symptoms correlated r = 0.75 
between self-ratings and interview, confirming the high validity of the SOMS. 
 
The 90-item version of the Symptom Checklist-90 Revised (Derogatis, 1994) reveals different 
aspects of psychopathology; it assesses patients’ current symptoms within a specified and 
optimal point-in-time (i.e., the past 7 days). The SCL-90-R includes three global index scales 
and nine symptom scales that were based on factor analysis and that include diagnostic-
specific and non-specific symptoms. Patients are instructed to rate mental health symptoms 
that have “bothered” them within the past 7 days on a 5-point scale (0–4) ranging from “Not 
at All” (i.e., a “0” rating) to “Extremely” (i.e., a “4” rating). The symptom scales include the 
Somatization, Obsessive-Compulsive, Interpersonal Sensitivity, Depression, Anxiety, 
Hostility, Phobic Anxiety, Paranoid Ideation, and Psychoticism scales. The SCL-90-R index 
scales include the Positive Symptom Total, Positive Symptom Distress Index, and Global 
Severity Index. SCL-90-R index and symptom scale scores are represented as T-scores, 
with a mean of 50 and a standard deviation of 10. Higher T-scores reflect greater number 
and/or severity of patient self-reported symptoms. We defined a “clinically significant” score 
to be a T-score of 63 or higher, based on the recommendations reported in Derogatis (1994). 
The TAS-26 was developed to measure alexithymia, a trait that can be characterized as the 
inability to identify and describe one’s own emotions and those of others (Sifneos, 1973). The 
original version was developed as a standardized self-assessment questionnaire by Taylor et 
al. (1985;19929. The authorized German version (TAS-26) has subsequently been 
developed by Kupfer et al., (2000;2001), which consists of 26 items that can be rated on a 5-
point Likert scale, was used in the present study to assess the presence and severity of 
alexithymia in the participants. A three-factor structure has been replicated in clinical and 
non-clinical groups: This measure includes 26 items that generate scores on three 
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dimensions: “difficulty identifying feelings”; “difficulty describing feelings” and “externally 
orientated thinking”. The German version was validated with a representative population 
sample (n=2,084) and shows adequate internal consistencies ranging between r=.67 and 
r=.84. The overall TAS-26 scores range from 18 to 90, because only 18 of the 26 items are 
used to calculate the TAS scores. Scores over raw-value 54 (respectively T-score 61) on the 
TAS-26 are taken to indicate significant alexithymia and this cut-off point is used to 
distinguish alexithymic and non-alexithymic individuals.  
The Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) was included in the 
present study to provide an observer-rated measure of depression severity. This assessment 
was conducted by a fully trained psychiatrist (P.G.F). The 21-item Beck-Depression-
Inventory (BDI; Beck et al., 1961) was utilised in the present study to provide an index of self-
rated depression severity.  
 
2.4. Assessment of Serum Levels of Interleukines 
Blood was drawn for routine evaluation (hematology, chemistry), and hormones (thyroid 
hormones, luteinizing hormone, folliculo-stimulating hormone, prolactin, progesterone, 
oestrogens, testosterone, cortisol), immunophenotyping, and serum cytokine levels. 
Hematology was measured with an automated hematologic counter (Sysmex, SE 9000). 
Serum samples were centrifuged and serum was frozen in aliquots at -20°C. Aliquots were 
defrosted, a standard curve of cytokines was established, and serum levels of the different 
interleukines (sIL-2 Rα, IL-4, IL-6, IL-10, IL-12) were calculated (pg/ml) by using the 
quantikine® high sensitivity Enzyme Linked Immunosorbent Assay (ELISA) kit from R&D 
systems, Wiesbaden, Germany. Means of duplicate samples were used for calculation of the 
serum levels. The procedure was performed as recommended by the manufacturer. 
Unspecific laboratory findings in our asymptomatic patients (e.g. lymphopenia) were not 
assumed to indicate an ongoing infection, because these findings were related to a possible 
immunopathology in association with SFD. Infectious and inflammatory diseases, which 
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could interfere with serum cytokine detection, were excluded by C reactive protein and 
erythrocyte sedimentation rate was within normal limits in all patients. Furthermore, a 
hormone screen was performed to exclude endocrine diseases as cause of altered serum 
cytokine levels. There were two considerations when selecting the panel of cytokines 
investigated in the present study: first we wanted to broadly cover the different immune 
functions, namely the Th1/Th2 dichotomy and the subsequent T/B cell activation that triggers 
cellular versus humoral immunity. IL-2 and IL-6 reflect general immune activation, whereas 
IL-10 and IL-4 are cytokines of the Th2 immunity, which inhibits T effector cells and activates 
B cell immunity and herewith the humeral antibody response. IL-12 is a member of the Th1 
immunity that mediates T cell mediated effector mechanisms. Second, serum levels must be 
detectable in physically healthy humans. IFNγ and TNFα  (Th1),  IL-5 and IL-13 (Th2), and 
IL-1α and IL-2 (general proinflammatory) are not detectable in healthy volunteers. Therefore 
sIL-2 Rα was chosen instead of IL2, as it has been shown in several investigations that sIL-2 
Rα correlates with increased B and T cell activation and immune system activation, e.g. 
rheumatoid arthritis or systemic lupus erythematosis (Wolf et al., 1988).  
 
 
2.5. Data analysis 
All data were analysed by SPSS for Windows© 11.5. The data were examined for normal 
distribution using the Shapiro-Wilk Test. Since most parameters were not normally 
distributed, nonparametric Mann-Whitney U-Tests were performed to establish if any 
observed differences between the two groups in serum levels of the different interleukines 
were significant. Mann Whitney U tests and fishers exact test were utilised to establish of the 
two groups differed significantly in terms of age, education, scores on the SOMS, SCl-90-R 
and TAS-26. The significance of any observed relationships between the serum levels of the 
interleukines and participant’ alexithymia (indexed by the participants’ scores on the TAS-26) 
were established using Spearman’s coefficient tests. In order to elucidate the relationship 
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between serum levels of the interleukines, participant characteristics, and alexithymia a 
forward stepwise multiple regression was conducted with serum levels (sIL-2 Rα, IL-4, IL-6, 
IL-10, IL-12), age and scores on the SCl-90-R entered as predictor variables and 
participants’ TAS-26 score entered as the dependent variable.  
3. Results 
3.1. Participant characteristics and psychopathology: 
Analysis of the participants characteristics revealed that the age of the patients with SFD 
(Mean=37.1, Standard deviation=10.4) did not differ significantly from the age of the controls 
(M=32.2, SD=6.5); p = 0.179. 45.8% of the patients and 55.6% of the control have a higher 
educational level (p=0.123). Analysis of the participants’ scores on the SOMS revealed that 
the patients with SFD exhibited elevated scores (Mean=16.3, SD=10.5), indicating that these 
patients showed signs of moderate to severe somatization. The HAM-D-score demonstrated 
with 13.4 (4.2) only moderate depression severity. Analysis of the participants’ subjective 
general psychiatric symptomatology (indexed by the participants’ scores on the SCL) 
revealed that the patients exhibited an elevated General symptomatic-score (Mean= 69.3, 
SD=12.1). Our patients exceeded the mean value (50) on all scales of SCL-90-R for 
somatization, obsessive-compulsiveness, social insecurity, depression, anxiety, aggression, 
phobic anxiety, paranoid ideation, and psychoticism (data not shown). 
 
3.2. Assessment of alexithymia: 
Analysis of the participants’ alexithymia (TAS-26) scores (presented in Table 2) revealed that 
the patients with SFD showed a TAS total score (T-value) of 55.7 (SD= 8.2). Further 
inspection revealed that the patients scored significantly higher on the “Difficulty identifying 
feelings” subscale (M=63.8, SD=12.1) over the cut-off T-value for TAS-scale 1 (Kupfer et al., 
2000, 2001). However, the patients’ scores in the subscale “Difficulty describing feelings” 
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(M=53.5, SD=8.7) and on the “Externally orientated thinking” subscale (M=47.4, SD=12.6) 
were not in the alexithymic range.  
 
 
 
3.3. Interleukines and alexithymia: 
Correlational analysis (presented in Table 3) revealed that sIL-2 Rα was significantly 
negatively related to the patients’ total TAS score; rs(24)= -0.54, p<0.05. This analysis also 
revealed a significant negative correlation between IL-4 serum levels and the patients’ total 
TAS-26 score; rs(24)=-0.49, p<0.05. There were no other significant relationships revealed by 
this analysis. 
 
In order to further elucidate the nature of these relationships a forward stepwise linear 
regression was conducted and revealed a significant model with sIL-2 Rα entered as the only 
significant predictor of the patients’ alexithymia scores (p = 0.041) that accounted for 20 % 
(16%) of the variance in the patients’ alexithymia (TAS-26) scores; R2= 0.201, R2 adjusted= 
0.159; F(1, 20) =4.8; p<0.05. 
 
3.4. Assessment of interleukines serum levels 
Analysis of the serum levels of the different interleukines detected for the patients with SFD 
and healthy controls (presented in Table 4) revealed that the level of IL-10 was significantly 
augmented in the patients (M=2.52 pg/ml, SD=2.7) in comparison to control group (M=0.65 
pg/ml, SD=1.3); U(N1=24, N2=9)=1.99, p<.0.05. Furthermore, patients with SFD exhibited 
elevated levels of IL-6 (M=2.61 pg/ml, SD=1.4) relative to the controls (M=1.01pg/m, 
SD=0.5), U(N1=24, N2=9)=3.61, p<0.001. On the other hand, the two groups did not differ 
significantly in terms of the serum levels of IL-4, IL-12 and sIL-2 Rα, all tests p>0.05. IL-4 
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levels were not detectable in the majority of probes, in patients only in 7 subjects and in the 
control group only in 3 subjects were detectable. 
 
3.5. Depression and interleukines: 
Inspection of the patients’ depression-scores only indicated moderate levels of depression; 
with 13.4 on the HAM-D (SD=4.2) and 18.8 on the BDI (SD=9.6). Importantly, correlational 
analyses demonstrated no significant relationships between the patients’ depression-scores 
(HAM-D and BDI) and the observed serum levels of the interleukines (data not shown).  
 
4. Discussion 
As expected we found a higher incidence of alexithymia in patients with SFD in comparison 
to the norms for the German population, regarding the TAS-scale “Difficulty identifying 
feelings”. This finding is in agreement with empirical findings which support a positive 
association between somatization and alexithymia (Bankier et al., 2001, De Gucht et al., 
2003). Consistent with our second hypothesis we found significant changes in the serum 
levels of the different interleukins in the patients with SFD relative to healthy controls. 
Specifically, the results revealed augmented IL-6 and IL-10 in the patient group. This pattern 
is interesting and suggests the immune response in SFD is complex. Interleukin-6 (IL-6) is a 
pro-inflammatory cytokine that is released in response to trauma or inflammation. Interleukin-
10 (IL-10) is a regulatory cytokine that suppresses TH1 response and induces TH2 response 
in general immune activation (Kidd 2003). The overproduction of IL-6 and IL-10 could lead to 
an increase of the TH2 response, which in turn is associated with augmented IgE antibody-
synthesis contributing to the pathophysiology of allergic disease. This proposition is 
supported by the unpublished findings of Pedrosa Gil et al. (2006), who reported significantly 
higher IgE serum levels in patients with SFD in comparison to healthy controls.  
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The finding of augmented IL-6 is inconsistent with a number of previous studies addressing 
immune response to SFD. Rief et al. (2001), for example, reported significantly lower serum 
levels of IL-6 in patients with somatization syndrome. However, the findings of the present 
study are in agreement with the stress-alexithymia hypothesis (Martin & Pihl, 1986), which 
posits that alexithymia is related to sympathetic overactivity. Furthermore, our findings are 
consistent with Cohen et al. (1999), who reported that higher levels of reported psychological 
stress were associated with higher IL-6 lavage concentrations in participants exposed to a 
viral challenge. However, it is far from conclusive as Peters et al. (1999) demonstrated that 
the uncontrollability of a stressful event was associated with reduced IL-6 concentrations 15-
30 minutes after the stressful event. Furthermore, Weber et al. (2002) observed that 
relaxation training significantly reduced perceived depression, stress and disturbance in a 
group of patients with tinnitus. However, this relaxation produced no significant change in IL-
6 or IL-10 serum levels. It should be noted that, Maes et al. (1999) found elevated serum 
interleukin (IL-6) concentration in posttraumatic stress disorder. Similarly, Sluzewska et al. 
(1996) reported elevated IL-6 concentrations in patients with major depression and in a 
recent study Tsao et al. (2006) found higher mRNA expressions of IL-1beta, IL-6, Interferon-
gamma, and TNF-alpha in a group of depressed patients relative to healthy controls. This is 
particularly notable as 87.5% of the patient sample in our present study exhibited comorbid 
depressive symptoms (either dysthymia or depressive reaction), thus it is plausible that the 
elevated IL-6 levels in the present study were a consequence of concurrent depression in the 
patients with SFD. However, the lack of a significant correlation, in the present study, 
between self- or clinician-rated depression severity and serum levels of the interleukins is 
contrary to this proposal.  
 
In contrast to our hypothesis the observed changes in IL-6 and IL-10 were not significantly 
related to the participants’ alexithymia scores. However, it should be noted that serum levels 
of IL-4 and soluble IL-2 Rα were negatively related to the patients’ alexithymia scores, thus 
high levels of alexithymia were associated with a reduction in the levels of these interleukins. 
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Although the function of the soluble IL-2 Rα is unclear, increased levels of the sIL-2 Rα in 
biological fluids have been reported to correlate with increased immune system activation 
(Waldmann, 1993; Fernandez-Botran, 1991). In our patients with SFD serum levels of sIL-2 
Rα were negatively correlated to alexithymia. A plausible explanation of these results is that 
patients with more alexithymic features may be suffering from (unnoticed) chronic stress 
reaction with concomitant activation of TH2 response and an associated reduction in TH1 
mediated immunity (indicated by the reduction in sIL-2 Rα). This proposal is consistent with 
the hypothesis of Guilbaud (2003), who reported that alexithymic individuals may suffer from 
unnoticed chronic stress with associated changes in endocrine and immune functions, such 
that the TH1/Th2-balance is shifted towards TH2-dominant-immunity (augmented IgE 
antibody synthesis) and away from the lower cell-mediated (Th1) immune response. The 
negative relationship between alexithymia and IL-4 serum levels, observed in the present 
study, is inconsistent with the findings of Corcos et al. (2004), who reported a positive 
association, in a group of seventeen healthy females, between serum levels of IL-4 and 
scores on the TAS-subscale “Difficulty in identifying feelings”. However, in our study IL-4 
levels was not detectable in the majority of the patients and therefore the results must be 
interpreted with care despite the statistical significance. In comparison to Corcos et al. 
(2004), who only included females, we investigated both genders in SFD in relation to 
alexithymia and interleukines. The effects are to be considered highly significant without 
however to regard the gender effect. It is valuable to examine the question of gender in 
further studies, because most studies in general population samples have found that men 
show more alexithymia than women do (Parker  et al., 2003; Lane et al., 1998), however 
other studies had observed no association between alexithymia and gender (Loas et al., 
2001).  
 
It is plausible that the observed changes in interleukin levels might have contributed to the 
somatic symptoms of the patients’ disorder. In line with this suggestion, Friedlander et al. 
(1997) proposed that SFD may result from the alexit
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elaborate affect, which gives rise to physiological arousal and a negative subjective state, 
which are not regulated by psychological strategies. This decoupling between subjective and 
physiological arousal when exposed to emotionally negative stimuli may increase alexithymic 
individuals' risks for stress-related illness (Stone and Nielson, 2001). Furthermore, there is 
evidence that physical and psychological stressors can provoke transient increases of 
proinflammatory interleukines (DeRijk et al., 1997; Zhou et al., 1993; Papanicolaou et al., 
1998). Finally, increased serum markers of inflammation have been found in obese human 
(Yoshida et al., 2006, Panagiotakos et al., 2005) although the mechanism of action and the 
primary event are unclear. With respect to our study, obesity may strengthen an otherwise 
activated inflammatory process (Oeser et al., 2005). Alternatively, obesity may be the result 
of a psychological illness and may herewith influence immune responses. As a result, 
upcoming studies comparing alexithymic patients with healthy controls must include the 
evaluation of the body mass index and, if possible, the fat distribution pattern as well. 
Another limitation considering our subject sample is the fact that the control group was not 
assessed as thoroughly regarding psychology measures as the patient group. However, it 
should be noted that the participants in the control group were screened prior to participation 
in the study and no evidence was found of psychological disturbance. Furthermore, the 
control sample was relatively small, which may have influenced our ability to detect subtle 
changes in interleukin levels. However, a strength of our study is that our sample of patients 
with SFD may have been less ill than the psychiatric patients reported in previous studies, as 
patients with major psychiatric diseases were excluded from our study. Most studies 
investigating immunological variables have used patients that were being treated with 
medication at the time of testing. This is important because increases in the circulating levels 
of TNF-α, IL-6 and other inflammatory cytokines have been reported in response to 
psychotropic drugs, antipsychotics, antidepressants, mood stabilizers (e.g. Pollmächer et al., 
2000; Hinze-Selch et al., 2000; Haack et al., 1999). Therefore, the presence of these drugs 
makes the interpretation of changes in interleukin levels difficult. Finding patients with SFD 
who are not currently medicated is difficult, thus a major strength of our study was that none 
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of our sample (patients and control group) was on medication at the time of testing. Although 
we have performed a comprehensive analysis of different immunological parameters, it 
remains difficult to correlate the alterations with the pathophysiology of SFD. 
 
In summary, our study represents the first investigation of the relationship between 
alexithymic symptoms in somatoform disorders and changes in the serum levels of important 
cytokines. Patients with SFD exhibited higher levels of IL-6 and IL-10 than did the controls 
indicating the presence of an inflammatory response in these patients, plausibly relating to 
their reported somatic pain. Although the levels of IL-6 and IL-10 were not associated with 
the patients’ alexithymia score, there was evidence of a relationship between alexithymia and 
an augmented TH-2 inflammatory response (indexed by reduced sIL-2 Rα).  
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Table 1: Demographic and clinical characteristics of patients with SFD (Standard 
deviations are presented in parentheses)  
Variable Patients with SFD 
(n=24) 
Age 37.1 (10.4) 
Gender (male/female) 8 / 16 
Higher education (%) 45.8% 
Somatization severity score (SOMS) 16.3 (10.5) 
General symptomatic (SCL-90-R) 69.3 (12.1) 
HAM-D 13.4 (4.2) 
BDI 18.8 (9.6) 
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Table 2: Mean alexithymia (TAS-26) scores for patients with SFD (Standard deviations 
are presented in parentheses)  
 
Scores on the TAS-26 
(T-values) 
Patients with SFD 
(n=24) 
 Mean (SD) 
Total Score 55.7 (8.2) 
”Difficulty identifying 
feelings“ subscale 63.8 (12.1) 
“Difficulty describing 
feelings” subscale 53.5 (8.7) 
“Externally orientated 
thinking” subscale 47.4 (12.6) 
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Table 3: Relationships between alexithymia (TAS-26 score) and serum levels of the 
different interleukins in the patients with SFD (n = 24) 
 
 
Type of Interleukin 
 
sIL-2 Rα IL-4 IL-6 IL-10 Il-12 
TAS, “Difficulty 
identifying feelings” 
subscale rs=-0.256 rs=0.025 rs=-0.204 rs=-0.083 rs=0.014 
TAS “Difficulty 
describing feelings” 
subscale rs=-0.306 rs=-0.071 rs=0.000 rs=0.133 rs=-0.088 
TAS “Externally 
orientated thinking” 
subscale rs=-0.027 rs=-0.248 rs=0.202 rs=-0.05 rs=0.346 
TAS Total score rs=-0.538* rs=-0.491* rs=0.162 rs=-0.031 rs=0.019 
 
* Significance (p<0.05) of correlations computed using Spearman’s tests   
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Table 4: Mean serum levels (pg/ml) of the different interleukins for the patients with 
SFD and healthy controls (Standard deviations are presented in parentheses) 
*Significance determined using Mann-Whitey U-Tests with adjusted alpha for multiple comparisons 
 
 
 
 
Type of 
Interleukin 
Patients with SFD 
(N=24) 
Healthy Controls 
(N=9) 
P-Value* 
sIL-2 Rα 884.1 (206.4) 898.5 (208.4) p = 0.894 
IL-4 0.004 (0.01) 0.32 (0.8) p = 0.185 
IL-6 2.61 (1.4) 1.01 (0.5)  p = 0.000 
IL-10 2.52 (2.7) 0.65 (1.3) P= 0.047 
Il-12 0.27 (0.1) 0.71 (1.4) p = 0.329 
